BIO Thanks Retiring FDA Commissioner Dr. Margaret Hamburg for Her Years of Commendable Service

Washington, D.C. (February 5, 2015) – Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood issued the following statement today regarding the announced retirement of Food and Drug Administration (FDA) Commissioner Dr. Margaret Hamburg:

“BIO extends our thanks and gratitude to Dr. Margaret Hamburg for her nearly six years of public service as the Commissioner of the FDA, a job that carries tremendous responsibility in protecting public health and advancing biomedical and agricultural innovation. Dr. Hamburg fulfilled these duties well and served at a time of historic advances in biotechnology and regulatory science.

“Of particular note, Dr. Hamburg presided over the implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) and the successful launch of the breakthrough therapy designation program and other expansions of expedited approval pathways. These programs have proven invaluable in bringing groundbreaking new therapies to patients more efficiently, while maintaining the FDA’s high standards for safety and efficacy. In 2014, the FDA approved more than 40 new drugs, the most in nearly two decades.

“We look forward to continuing to work with Dr. Hamburg and her successor to ensure that the FDA’s regulatory capabilities and science continue to keep pace with the tremendous progress taking place in biotechnology innovation.”

Upcoming BIO Events 

BIO CEO & Investor Conference
February 9-10, 2015
New York City, NY

BIO-Europe Spring
March 9-11, 2015
Paris, France

BIO Asia International Conference
March 24-25, 2015
Tokyo, Japan

BioEquity Europe
May 19-20, 2015
Vienna, Austria

BIO International Convention
June 15-18, 2015
Philadelphia, PA

###